2021
Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen
Olawoyin OM, Mehta S, Chouairi F, Gabrick KS, Avraham T, Pusztai L, Alperovich M. Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen. Plastic & Reconstructive Surgery 2021, 148: 1186-1196. PMID: 34644277, DOI: 10.1097/prs.0000000000008505.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapy regimensMicrovascular breast reconstructionNeoadjuvant chemotherapyChemotherapy regimensComplication rateFat necrosisBreast reconstructionImmune cellsCLINICAL QUESTION/LEVELMultivariate binary logistic regressionYale-New Haven HospitalAdministration of taxanesBreast Reconstruction ComplicationsInclusion of anthracyclinesNeoadjuvant chemotherapy regimenDosage of chemotherapyNew Haven HospitalNeoadjuvant chemotherapy completionLogistic regression modelsBinary logistic regressionOncologic historyTaxane administrationChemotherapy regimenChemotherapy completionPathologic response
2017
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals Of Oncology 2017, 28: 2420-2428. PMID: 28961844, PMCID: PMC5834134, DOI: 10.1093/annonc/mdx397.Peer-Reviewed Original ResearchConceptsHER2-negative primary breast cancerAdjuvant hormonal therapyPrimary breast cancerTriple-negative breast cancerEstrogen receptor positivityHormonal therapyBreast cancerER expressionNeoadjuvant chemotherapyOverall survivalReceptor positivityPathological complete response rateHER2-negative breast cancerStage IIHuman epidermal growth factor 2Better long-term outcomesEpidermal growth factor 2Complete response rateProgesterone receptor expressionLong-term outcomesNegative breast cancerTerms of pCRLogistic regression modelsDefinitive surgeryGrowth factor 2
2013
USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer
Bayraktar S, Barrera A, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. The Cancer Journal 2013, 19: 10-17. PMID: 23337751, PMCID: PMC3568679, DOI: 10.1097/ppo.0b013e3182801b3a.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyPathological complete responseBreast cancerKaplan-Meier product-limit methodBetter survival outcomesDisease-free survivalOverall survival rateRisk of recurrenceProduct-limit methodLogistic regression modelsNeoadjuvant therapyComplete responsePrognostic factorsSystemic therapyDisease recurrencePrognostic relevanceSurvival outcomesHigh riskPatientsSurvival rateTumorsCancerRecurrencePolymerase inhibitionUbiquitin-specific protease family
2011
Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Arun B, Bayraktar S, Liu DD, Barrera A, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. Journal Of Clinical Oncology 2011, 29: 3739-3746. PMID: 21900106, PMCID: PMC4874218, DOI: 10.1200/jco.2011.35.2682.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic chemotherapyRelapse-free survivalBreast cancerOS ratesOverall survivalBRCA1 carriersBRCA statusBRCA2 mutationsKaplan-Meier product-limit methodPathologic complete response rateComplete response rateNeoadjuvant systemic therapySingle institution experienceEstrogen receptor negativityBRCA mutation carriersBRCA1 statusIndependent significant predictorsProduct-limit methodMultivariate logistic modelBRCA genetic testingSporadic breast cancerLogistic regression modelsBRCA noncarriersTrastuzumab useSystemic chemotherapy
2009
Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables
Rouzier R, Coutant C, Lesieur B, Mazouni C, Incitti R, Natowicz R, Pusztai L. Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables. Breast Cancer Research And Treatment 2009, 117: 325-331. PMID: 19152025, DOI: 10.1007/s10549-009-0308-2.Peer-Reviewed Original Research
2007
Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients
Sun A, Yu T, Wang L, Lu J, Gonzales G, Pusztai L, Singletary S, Ross M, Wei Q, Buchholz T. Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients. Journal Of Clinical Oncology 2007, 25: 574-574. DOI: 10.1200/jco.2007.25.18_suppl.574.Peer-Reviewed Original ResearchBreast cancer patientsAbsolute neutrophil countChemotherapy-induced neutropenic feverNeutropenic feverCancer patientsC polymorphismChemotherapy-induced bone marrow toxicityGene polymorphismsMultivariable logistical regression analysisMultivariable logistic regression modelGrowth factor supportPolymerase chain reaction-restriction fragment length polymorphism methodBone marrow toxicityTwo-sided ChiFragment length polymorphism methodGrowth factor useLogistical regression analysisLength polymorphism methodLogistic regression modelsInstitutional review boardNBS1 geneSystemic chemotherapyNeutrophil countChemotherapy administrationFactor supportProspective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes
Ueno N, Kim S, Symmans W, Detry M, Pusztai L, Sanchez L, Ishihara H, Hortobagyi G, Noguchi S. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes. Journal Of Clinical Oncology 2007, 25: 586-586. DOI: 10.1200/jco.2007.25.18_suppl.586.Peer-Reviewed Original ResearchClinical responseTaxane sensitivityPreoperative therapyPrognostic factorsHER2 tumorsProspective studyBreast cancerDocetaxel/capecitabineDocetaxel/doxorubicinTaxane-containing regimensLarge prospective studiesPrimary breast cancerClinical prognostic factorsHER2- breast cancerNovel predictive markerCyclin-dependent kinase 1Breast tumor responseLogistic regression modelsEvaluable ptsAdjuvant therapyClinical outcomesPreclinical findingsPredictive markerTumor responseHER2 overexpression
2006
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
Rouzier R, Pusztai L, Garbay J, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 2006, 107: 1459-1466. PMID: 16948128, DOI: 10.1002/cncr.22177.Peer-Reviewed Original ResearchConceptsResidual tumor sizeBreast conservation therapyNeoadjuvant chemotherapyBreast conservation surgeryBreast cancer patientsTumor sizeConservation therapyBreast conservationConservation surgeryCancer patientsAnthracycline-based neoadjuvant chemotherapyD. Anderson Cancer CenterPaclitaxel neoadjuvant chemotherapyPreoperative chemotherapy regimenPreoperative chemotherapy regimensSuccessful conservative surgeryValidation of nomogramsInstitut Gustave RoussyAnderson Cancer CenterLogistic regression modelsChemotherapy regimenChemotherapy regimensConservative surgeryClinicopathologic dataCancer Center